<?xml version='1.0' encoding='utf-8'?>
<document id="26004270"><sentence text="Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C."><entity charOffset="50-60" id="DDI-PubMed.26004270.s1.e0" text="telaprevir" /></sentence><sentence text="Telaprevir is one of the first direct-acting antiviral drugs approved for the treatment of the hepatitis C virus (HCV) genotype 1"><entity charOffset="0-10" id="DDI-PubMed.26004270.s2.e0" text="Telaprevir" /></sentence><sentence text=" Following its approval in 2011, new data regarding the pharmacokinetics and pharmacodynamics were reported, leading to important clinical applications" /><sentence text="" /><sentence text="This article reviews the pharmacokinetic and pharmacodynamic properties of telaprevir for the treatment of the HCV"><entity charOffset="75-85" id="DDI-PubMed.26004270.s5.e0" text="telaprevir" /></sentence><sentence text=" The areas covered include data regarding the drug's absorption, distribution, metabolism and excretion, in addition to the antiviral activity strategy such as the clinical dose selection and treatment duration" /><sentence text="" /><sentence text="Telaprevir presents several pharmacological properties that could limit its administration such a high-fat, high-calorie meal; the need to be administrated with pegylated IFN plus ribavirin; and the drug-drug interaction profile"><entity charOffset="0-10" id="DDI-PubMed.26004270.s8.e0" text="Telaprevir" /><entity charOffset="180-189" id="DDI-PubMed.26004270.s8.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.26004270.s8.e0" e2="DDI-PubMed.26004270.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26004270.s8.e0" e2="DDI-PubMed.26004270.s8.e1" /></sentence><sentence text=" As a consequence and considering the new therapeutic arsenal against the HCV, the use of telaprevir as part of HCV therapy will be limited"><entity charOffset="90-100" id="DDI-PubMed.26004270.s9.e0" text="telaprevir" /></sentence><sentence text="" /></document>